October 1, 2007


Bad Bugs on the Run


Bad Bugs logo

The Society scored a victory recently on its “Bad Bugs, No Drugs” initiative (www.idsociety.org/badbugsnodrugs) when Congress reauthorized the Food and Drug Administration (FDA) Prescription Drug User Fee Act on Sept. 21. The new law includes several IDSA-backed provisions that would remove obstacles from antibiotic drug review and provide incentives to strengthen the drug pipeline.

Among other things, the law requires FDA to:

  1. establish and update clinical susceptibility concentrations—the breakpoints at which a bacterium is likely resistant to antibiotics
  2. hold a public meeting to discuss the eligibility of antibiotics for certain orphan drug incentives
  3. publish guidelines for anti-infective clinical trials by September 2008
  4. provide priority-review vouchers in exchange for drugs approved to treat tropical diseases

Unfortunately, lawmakers in the House of Representatives removed an IDSA-backed provision that would have granted new market exclusivity to some antibiotics. IDSA will continue to push for this incentive.

In another important development, the “Strategies To Address Antimicrobial Resistance” (STAAR) Act was introduced on Sept. 27 by Reps. Jim Matheson (D-UT) and Mike Ferguson (R-NJ). Co-sponsors include Reps. Tammy Baldwin (D-WI) and Henry Waxman (D-CA).

This IDSA-initiated bill would improve the nation’s capacity to control resistance by establishing a network of experts across the country to collaborate with the Centers for Disease Control and Prevention (CDC) and conduct regional monitoring of resistant organisms as they occur—a kind of “snapshot” to pick up on problems early.

Researchers in the network also would work with CDC and the National Institutes of Health to find ways to slow the development of resistance. They would test potential interventions and perhaps new drugs, diagnostics, and other products as they move through the pipeline.

The STAAR Act would create an advisory board of infectious diseases, public health, and veterinary experts to advise the federal government on reducing resistance.

It would create an Office of Antimicrobial Resistance in the Department of Health and Human Services to build upon existing efforts and to better coordinate, help plan, and guide the government’s response to resistance.


Read more about the new FDA law.

Find out more about the proposed STAAR Act.

For the latest data from CDC on methicillin-resistant Staphylococcus aureus, see Klevens RM, et al.  JAMA. 2007;298:1763-1771, http://jama.ama-assn.org/cgi/content/full/298/15/1763.


< Previous Article | Next Article >

Thinking Outside the Box
ART, Circumcision, STI Treatment as HIV Prevention
Global Surveillance, Vaccine Use Key to Controlling Seasonal Influenza
Bad Bugs on the Run
IDSA Advocacy Update
HIV PrEP: Should We or Shouldn’t We?
Keep Up with Drug Approvals, Recalls, Adverse Events
Lyme Disease: When Symptoms Don’t Improve
Alternative Approaches, Possible Vaccines Against MRSA Infections
New Hope for Viral Suppression in All HIV Patients
Resistant Staph: Use One Drug or a Combination?
Congratulations to the 2007 Society Award Recipients
Winners of the 2007 IDSA/SHEA Advancements in MRSA Awards
Congratulations to This Year’s 50 Outstanding Scholars!
IDSA Announces New Board Members
Welcome, New IDSA Members!
Electronic Tools for Infectious Diseases Practitioners
From the President
Public Reporting of HAIs May Have Unintended Consequences
Treatment Options for C. difficile
XDR TB: Where it Came From, Where We’re Going
Search Back Issues
Forward this Issue
Print-Friendly Version

© Copyright IDSA 2008 Infectious Diseases Society of America 1300 Wilson Boulevard, Suite 300 Arlington, VA 22209 info@idsociety.org

Home Page Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA